Literature DB >> 12925688

Beta-agonists and asthma: too much of a good thing?

Stephanie A Shore1, Jeffrey M Drazen.   

Abstract

In an unusual paradox, asthmatics who are chronically treated with bronchodilating beta-agonists sometimes experience a worsening of their condition. A new study describes one possible mechanism and reveals a potential new therapeutic target in the treatment of asthma.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12925688      PMCID： PMC171402          DOI： 10.1172/JCI19642

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  Beta-agonist intrinsic efficacy: measurement and clinical significance.

Authors:  Nicola A Hanania; Amir Sharafkhaneh; Roger Barber; Burton F Dickey
Journal:  Am J Respir Crit Care Med       Date:  2002-05-15       Impact factor: 21.405

2.  Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism.

Authors:  D R Taylor; J M Drazen; G P Herbison; C N Yandava; R J Hancox; G I Town
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

Review 3.  Regulation of G protein-coupled receptor signaling by scaffold proteins.

Authors:  Randy A Hall; Robert J Lefkowitz
Journal:  Circ Res       Date:  2002-10-18       Impact factor: 17.367

4.  Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling.

Authors:  Michael Roth; Peter R A Johnson; Jochen J Rüdiger; Gregory G King; Qi Ge; Janette K Burgess; Gary Anderson; Michael Tamm; Judith L Black
Journal:  Lancet       Date:  2002-10-26       Impact factor: 79.321

5.  The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma.

Authors:  E Israel; J M Drazen; S B Liggett; H A Boushey; R M Cherniack; V M Chinchilli; D M Cooper; J V Fahy; J E Fish; J G Ford; M Kraft; S Kunselman; S C Lazarus; R F Lemanske; R J Martin; D E McLean; S P Peters; E K Silverman; C A Sorkness; S J Szefler; S T Weiss; C N Yandava
Journal:  Am J Respir Crit Care Med       Date:  2000-07       Impact factor: 21.405

6.  Inhibitors of mitogen-activated protein kinases differentially regulate eosinophil-activating cytokine release from human airway smooth muscle.

Authors:  M P Hallsworth; L M Moir; D Lai; S J Hirst
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

7.  Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids.

Authors:  L Pang; A J Knox
Journal:  FASEB J       Date:  2001-01       Impact factor: 5.191

8.  Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases.

Authors:  Judith C W Mak; Takeshi Hisada; Michael Salmon; Peter J Barnes; K Fan Chung
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

9.  MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged p42/p44 activation.

Authors:  M J Orsini; V P Krymskaya; A J Eszterhas; J L Benovic; R A Panettieri; R B Penn
Journal:  Am J Physiol       Date:  1999-09

10.  Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes.

Authors:  W Z Zhu; M Zheng; W J Koch; R J Lefkowitz; B K Kobilka; R P Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205
View more
  17 in total

Review 1.  Regulation of β-adrenergic receptor function: an emphasis on receptor resensitization.

Authors:  Neelakantan T Vasudevan; Maradumane L Mohan; Shyamal K Goswami; Sathyamangla V Naga Prasad
Journal:  Cell Cycle       Date:  2011-11-01       Impact factor: 4.534

2.  A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation.

Authors:  Xiaofeng Jiang; Hui Pan; Joseph F Nabhan; Ramaswamy Krishnan; Cynthia Koziol-White; Reynold A Panettieri; Quan Lu
Journal:  FASEB J       Date:  2012-01-25       Impact factor: 5.191

3.  beta-Adrenergic receptor polymorphisms and response to salmeterol.

Authors:  Michael E Wechsler; Erik Lehman; Stephen C Lazarus; Robert F Lemanske; Homer A Boushey; Aaron Deykin; John V Fahy; Christine A Sorkness; Vernon M Chinchilli; Timothy J Craig; Emily DiMango; Monica Kraft; Frank Leone; Richard J Martin; Stephen P Peters; Stanley J Szefler; Wenlei Liu; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2005-12-01       Impact factor: 21.405

4.  The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.

Authors:  Nicola A Hanania; Supria Singh; Rami El-Wali; Michael Flashner; Amie E Franklin; William J Garner; Burton F Dickey; Sergio Parra; Stephen Ruoss; Felix Shardonofsky; Brian J O'Connor; Clive Page; Richard A Bond
Journal:  Pulm Pharmacol Ther       Date:  2007-07-17       Impact factor: 3.410

5.  Heat Shock-Related Protein 20 Peptide Decreases Human Airway Constriction Downstream of β2-Adrenergic Receptor.

Authors:  Alex Banathy; Joyce Cheung-Flynn; Kasia Goleniewska; Kelly L Boyd; Dawn C Newcomb; R Stokes Peebles; Padmini Komalavilas
Journal:  Am J Respir Cell Mol Biol       Date:  2016-08       Impact factor: 6.914

6.  Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model.

Authors:  Long P Nguyen; Rui Lin; Sergio Parra; Ozozoma Omoluabi; Nicola A Hanania; Michael J Tuvim; Brian J Knoll; Burton F Dickey; Richard A Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

7.  Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype.

Authors:  Radhika Joshi; Daniel Valdez; Hosu Kim; Douglas C Eikenburg; Brian J Knoll; Richard A Bond
Journal:  Pulm Pharmacol Ther       Date:  2017-07-17       Impact factor: 3.410

8.  In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator.

Authors:  Jeffrey D Edelson; Marie Makhlina; Kevin R Silvester; Shailesh S Vengurlekar; Xiaomei Chen; Jie Zhang; Cynthia J Koziol-White; Philip R Cooper; Trevor J Hallam; Douglas W P Hay; Reynold A Panettieri
Journal:  Pulm Pharmacol Ther       Date:  2012-11-12       Impact factor: 3.410

9.  Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.

Authors:  Michael E Wechsler; Susan J Kunselman; Vernon M Chinchilli; Eugene Bleecker; Homer A Boushey; William J Calhoun; Bill T Ameredes; Mario Castro; Timothy J Craig; Loren Denlinger; John V Fahy; Nizar Jarjour; Shamsah Kazani; Sophia Kim; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Amy Markezich; Richard J Martin; Perdita Permaul; Stephen P Peters; Joe Ramsdell; Christine A Sorkness; E Rand Sutherland; Stanley J Szefler; Michael J Walter; Stephen I Wasserman; Elliot Israel
Journal:  Lancet       Date:  2009-11-21       Impact factor: 79.321

10.  β2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model.

Authors:  Vaidehi J Thanawala; Gloria S Forkuo; Nour Al-Sawalha; Zoulikha Azzegagh; Long P Nguyen; Jason L Eriksen; Michael J Tuvim; Thomas W Lowder; Burton F Dickey; Brian J Knoll; Julia K L Walker; Richard A Bond
Journal:  Am J Respir Cell Mol Biol       Date:  2012-11-29       Impact factor: 6.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.